Stock 603168 ZHEJIANG SHAPUAISI PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.

Equities

603168

CNE100001TG0

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 01/07/2024 BST 		5-day change 1st Jan Change
7.37 CNY +0.27% Intraday chart for Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. -1.86% -45.04%
04-29 Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-19 Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Shapuaisi Pharma Gets Marketing Authorization for Moxifloxacin Hydrochloride Eye Drops
MT
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Shanghai Lechun Biotechnology Co., Ltd. sign a share transfer agreement to acquire a 14.5% stake in Advanced Sterile Solutions Biotechnology Co., Ltd. from Shanghai Changgeng Industrial Development Co., Ltd. and Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. for CNY 40.6 million.
CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. agreed to acquire Qingdao Shikang Eye Hospital Co., Ltd. from Shanghai Fangzhi Medical Management Co., Ltd. for CNY 66.5 million
CI
Zhejiang Shapuaisi Pharma Shareholder Boosts Stake Through $44 Million Deal
MT
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
Shanghai Tonghui Medical Management Co., Ltd. completed the acquisition of 5.43% stake in Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. from Chen Dekang.
CI
Shanghai Tonghui Medical Management Co., Ltd. signed a share transfer agreement to acquire 5.43% stake in Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. from Chen Dekang for approximately CNY 400 million.
CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
Jilin Yueshi Tianbo Pharmaceutical Co., Ltd. signed an agreement to acquire Shapuaisi Qiangshen Pharmaceutical Co., Ltd. from Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. for CNY 82 million.
CI
Zhejiang Shapuaisi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 603168 Stock
  4. News Zhejiang Shapuaisi Pharmaceutical Co.,Ltd.
  5. Highlights